156 related articles for article (PubMed ID: 11555609)
1. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Li WW; Takahashi N; Jhanwar S; Cordon-Cardo C; Elisseyeff Y; Jimeno J; Faircloth G; Bertino JR
Clin Cancer Res; 2001 Sep; 7(9):2908-11. PubMed ID: 11555609
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Takahashi N; Li WW; Banerjee D; Scotto KW; Bertino JR
Clin Cancer Res; 2001 Oct; 7(10):3251-7. PubMed ID: 11595721
[TBL] [Abstract][Full Text] [Related]
4. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
Takahashi N; Li W; Banerjee D; Guan Y; Wada-Takahashi Y; Brennan MF; Chou TC; Scotto KW; Bertino JR
Cancer Res; 2002 Dec; 62(23):6909-15. PubMed ID: 12460906
[TBL] [Abstract][Full Text] [Related]
5. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
Poindessous V; Koeppel F; Raymond E; Comisso M; Waters SJ; Larsen AK
Clin Cancer Res; 2003 Jul; 9(7):2817-25. PubMed ID: 12855662
[TBL] [Abstract][Full Text] [Related]
6. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Moneo V; Serelde BG; Fominaya J; Leal JF; Blanco-Aparicio C; Romero L; Sánchez-Beato M; Cigudosa JC; Tercero JC; Piris MA; Jimeno J; Carnero A
J Cell Biochem; 2007 Feb; 100(2):339-48. PubMed ID: 16888811
[TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
Kanzaki A; Takebayashi Y; Ren XQ; Miyashita H; Mori S; Akiyama S; Pommier Y
Mol Cancer Ther; 2002 Dec; 1(14):1327-34. PubMed ID: 12516966
[TBL] [Abstract][Full Text] [Related]
8. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
10. ET-743: a novel agent with activity in soft tissue sarcomas.
Fayette J; Coquard IR; Alberti L; Ranchère D; Boyle H; Blay JY
Oncologist; 2005; 10(10):827-32. PubMed ID: 16314293
[TBL] [Abstract][Full Text] [Related]
11. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
Meco D; Colombo T; Ubezio P; Zucchetti M; Zaffaroni M; Riccardi A; Faircloth G; Jose J; D'Incalci M; Riccardi R
Cancer Chemother Pharmacol; 2003 Aug; 52(2):131-8. PubMed ID: 12783202
[TBL] [Abstract][Full Text] [Related]
12. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
13. Effect of anticancer drugs on production of transforming growth factor and expression of p53 AND Bcl-2 proteins by MCF-7 and T47D cell lines of human breast carcinoma.
Stoika RS; Yakymovych IA; Kashchak NI; Boyko MM; Korynevska AV; Klyuchyvska OY; Shafranska GI; Yakymovych MY; Zhylchuk VY; Kudryavets YY; Vorontsova AL
Exp Oncol; 2008 Mar; 30(1):35-41. PubMed ID: 18438339
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743).
Erba E; Bergamaschi D; Bassano L; Ronzoni S; Di Liberti G; Muradore I; Vignati S; Faircloth G; Jimeno J; D'Incalci M
Br J Cancer; 2000 May; 82(10):1732-9. PubMed ID: 10817511
[TBL] [Abstract][Full Text] [Related]
15. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
16. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
17. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
18. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
Valoti G; Nicoletti MI; Pellegrino A; Jimeno J; Hendriks H; D'Incalci M; Faircloth G; Giavazzi R
Clin Cancer Res; 1998 Aug; 4(8):1977-83. PubMed ID: 9717828
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
20. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
